Verteporfin, an inhibitor of YAP/TAZ, is also confirmed to mimic the action of knocking YAP and TAZ down and is able to enhance the sensitivity of endometrial carcinoma cells to progestin treatment. This evidence concerns the gene YAP1 and endometrial carcinoma.